What Happened?
Cambridge, MA-based Fulcrum-Therapeutics Resigned Esther Rajavelu as Chief Financial Officer
About the Company
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
About the Person
Esther Rajavelu is Chief Financial Officer and Chief Business Officer at Spero Therapeutics. Previously, Esther held various senior HR leadership roles in the industry.
Info Source
News
Short Profile